Literature DB >> 15191815

Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein.

Annette George1, Christoph Kleinschnitz, Marek Zelenka, Jörg Brinkhoff, Guido Stoll, Claudia Sommer.   

Abstract

We used enzyme-linked immunoassay (ELISA), immunohistochemistry (IHC), and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to determine whether interleukin (IL)-10 protein is changed after unilateral crush or chronic constriction injury (CCI) of mouse or rat sciatic nerve and whether IL-10 protein and mRNA are differentially regulated. In the mouse sciatic nerve, IL-10 protein declined rapidly to 10-20% of baseline early after crush or CCI, while the IL10 mRNA was up-regulated with a maximum on Days 1 and 3. In the rat sciatic nerve, IL-10 protein was significantly reduced on Day 3 after CCI, and IL-10 mRNA was up-regulated in both models. These results suggest that changes of the local cytokine network during wallerian degeneration include an early deficiency of the antiinflammatory cytokine IL-10 despite up-regulation at the mRNA level.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15191815     DOI: 10.1016/j.expneurol.2004.02.011

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  12 in total

Review 1.  "Listening" and "talking" to neurons: implications of immune activation for pain control and increasing the efficacy of opioids.

Authors:  Linda R Watkins; Mark R Hutchinson; Erin D Milligan; Steven F Maier
Journal:  Brain Res Rev       Date:  2007-07-13

Review 2.  [Cytokine regulation and pain. Results of experimental and clinical research].

Authors:  N Uçeyler; C Sommer
Journal:  Schmerz       Date:  2008-12       Impact factor: 1.107

Review 3.  The neuroimmunology of degeneration and regeneration in the peripheral nervous system.

Authors:  A DeFrancesco-Lisowitz; J A Lindborg; J P Niemi; R E Zigmond
Journal:  Neuroscience       Date:  2014-09-19       Impact factor: 3.590

Review 4.  The therapeutic potential of interleukin-10 in neuroimmune diseases.

Authors:  A J Kwilasz; P M Grace; P Serbedzija; S F Maier; L R Watkins
Journal:  Neuropharmacology       Date:  2014-11-04       Impact factor: 5.250

5.  Treatment of neuroinflammation by soluble tumor necrosis factor receptor Type II fused to a thermally responsive carrier.

Authors:  Mohammed F Shamji; Liufang Jing; Jun Chen; Priscilla Hwang; Odelia Ghodsizadeh; Allan H Friedman; William J Richardson; Lori A Setton
Journal:  J Neurosurg Spine       Date:  2008-08

Review 6.  Spinal interleukin-10 therapy to treat peripheral neuropathic pain.

Authors:  Erin D Milligan; Kathryn R Penzkover; Ryan G Soderquist; Melissa J Mahoney
Journal:  Neuromodulation       Date:  2012-06-01

Review 7.  Balancing the immune response in the brain: IL-10 and its regulation.

Authors:  Diogo Lobo-Silva; Guilhermina M Carriche; A Gil Castro; Susana Roque; Margarida Saraiva
Journal:  J Neuroinflammation       Date:  2016-11-24       Impact factor: 8.322

Review 8.  The Glia Response after Peripheral Nerve Injury: A Comparison between Schwann Cells and Olfactory Ensheathing Cells and Their Uses for Neural Regenerative Therapies.

Authors:  Matthew J Barton; James St John; Mary Clarke; Alison Wright; Jenny Ekberg
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

9.  Transcriptional Profiling at High Temporal Resolution Reveals Robust Immune/Inflammatory Responses during Rat Sciatic Nerve Recovery.

Authors:  Lingyan Xing; Qiong Cheng; Guangbin Zha; Sheng Yi
Journal:  Mediators Inflamm       Date:  2017-04-12       Impact factor: 4.711

10.  CD300f immunoreceptor contributes to peripheral nerve regeneration by the modulation of macrophage inflammatory phenotype.

Authors:  Hugo Peluffo; Patricia Solari-Saquieres; Maria Luciana Negro-Demontel; Isaac Francos-Quijorna; Xavier Navarro; Ruben López-Vales; Joan Sayós; Natalia Lago
Journal:  J Neuroinflammation       Date:  2015-08-12       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.